- Short communication
- Open Access
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
Molecular Cancer volume 11, Article number: 72 (2012)
Resistance to tyrosine kinase inhibitors (TKIs) remains a challenge in management of patients with chronic myeloid leukemia (CML). A better understanding of the BCR-ABL signalling network may lead to better therapy.
Here we report the discovery of a novel downstream target of BCR-ABL signalling, PRL-3 (PTP4A3), an oncogenic tyrosine phosphatase. Analysis of CML cancer cell lines and CML patient samples reveals the upregulation of PRL-3. Inhibition of BCR-ABL signalling either by Imatinib or by RNAi silencing BCR-ABL reduces PRL-3 and increases cleavage of PARP. In contrast, the amount of PRL-3 protein remains constant or even increased in response to Imatinib treatment in drug resistant cells expressing P210 T315I. Finally, analysis with specific shRNA shows PRL-3 involvement in the proliferation and self-renewal of CML cells.
These data support a role for PRL-3 in BCR-ABL signalling and CML biology and may be a potential therapeutic target downstream of BCR-ABL in TKI resistant mutant cells.
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy with a hallmark cytogenetic abnormality, i.e., the BCR-ABL fusion oncogene, resulting from the reciprocal translocation of chromosomes 9 and 22 [also known as Philadelphia (Ph) chromosome]. CML is the best and most successful disease model for tyrosine kinase inhibitor (TKI) therapy[2, 3]. Unfortunately, acquired resistance can develop during the course of treatment. Effective therapies that can overcome resistance still remain a challenge for the clinical management of CML[2, 4]. The mechanism of BCR-ABL induced transformation and signaling transduction networks have been intensively characterized over the decades[5–7]. However, new discoveries related to the BCR-ABL signaling pathway and mechanisms of TKI resistance continues to emerge, leading to a better understanding of disease progression and development of novel therapy[8–10].
Protein-tyrosine phosphatase of regenerating liver 3 (PRL-3, encoded by protein tyrosine phosphatase type IVA 3, PTP4A3) belongs to class I cysteine-based protein tyrosine phosphatases (PTPs) with dual-specificity[11–13]. PRL-3 has been identified as a critical player in cancer cell metastasis, invasion, migration, and tumor angiogenesis[11, 14–16]. The association between elevated PRL-3 and the development of various human cancers has been validated in a wide range of solid tumors[11, 14, 15] and multiple myeloma.
We recently discovered that poly(rC) binding protein 1 (PCPB1, also known as heterogenous nuclear ribonucleoprotein E1, hnRNP-E1) inhibited PRL-3 protein through binding 5’-UTR (untranslated region) of PRL-3 mRNA and showed that PRL-3, acting as a downstream target of the internal tandem duplication (ITD) of fms-like tyrosine kinase (FLT3) signaling, was implicated in FLT3 inhibitor therapy in acute myeloid leukemia (AML). Furthermore, PRL-3 also has been demonstrated as an independent prognostic parameter for poor overall survival (OS) and event-free survival (EFS) in AML. Importantly, targeting intracellular PRL-3 protein suppressed cancer growth. In the present study, we hypothesize that PRL-3 might be involved in leukemogenesis of human CML.
Overexprsesion of PRL-3 in CML cell lines and primary patient samples
A search of the Gene Expression Atlas (http://www.ebi.ac.uk/gxa/gene/ENSG00000184489) showed that the expression level of PRL-3 was highest in CML among 950 human cancer cell lines covering 32 different types of cancers (Dataset code: E-MTAB-37), suggesting a potential role of PRL-3 in CML pathogenesis (Figure1A). To further confirm PRL-3 expression, we examined PRL-3 protein levels in a panel of CML cell lines and primary CML BM samples. By immunoblot analysis,(Additional file1) we observed strong PRL-3 protein expression in two human CML cell lines (K562 and KCL-22, Figure1B), murine hematopoitic cells expressing WT and mutant BCR-ABL constructs (P210 WT, P210 T315I, P210 M351T and P210 H396R, Figure1B middle), and primary BM samples from CML patients (Figure1B right). It is worth noting that PRL-3 is either not expressed or minimally expressed in bone marrow cells from 3 normal controls (NC) or parental BaF3 cells (Figure1B). Altogether, our data obtained from Western blot analysis of CML cell lines and primary CML samples, as well as the analysis of a publicly available gene expression dataset demonstrated over-expression of PRL-3 in CML.
Imatinib suppressed PRL-3 through inhibition of STAT pathway
Imatinib blocks the binding of ATP to the BCR-ABL tyrosine kinase[22, 23], and is currently used as the first-line treatment for CML[2, 4]. To establish a connection between BCR-ABL signalling and PRL-3 expression, we treated human CML cell lines, K562 and KCL-22 cells with Imatinib and assessed the expression of PRL-3. Western blot analysis demonstrated that Imatinib dose-dependently decreased p-CrkL (a surrogate marker of BCR-ABL kinase activity), p-STAT3, p-STAT5, as well as PRL-3 (Figure2A). Consistent with the effective inhibition of oncogenic BCR-ABL signalling, cleaved-PARP, a hallmark of apoptosis was increased as a response to the Imatinib treatment (Figure2A). We next tested whether Imatinib could induce PRL-3 protein down-regulation in BaF3 murine hematopoietic cells engineered to express either wild-type, or the Imatinib resistant T315I mutant P210 BCR-ABL. As expected, the expression of p-CrkL, p-STAT3 and PRL-3 was down-regulated in a dose-dependent manner in the imatinib sensitive P210 WT cells. In contrast, BCR-ABL activity in P210 T315I cells was resistant to Imatinib even at high doses (10 μM) as indicated by no change in p-CrkL. In this resistant cell line, PRL-3 was not downregulated but rather its level increased at higher doses of Imatinib (Figure2B). Surprisingly, p-STAT5 expression was almost completely abolished in both P210 WT and p210 T315I cells upon exposure to Imatinib (Figure2B). On the other hand, the down-regulation of PRL-3 correlated with the inhibition of STAT3. Consistent with inhibition of BCR-ABL, increased PARP cleavage fragment was observed in cells sensitive to Imatinib (K652, P210 WT), but not in resistant cells (P210 T315I) (Figure2B). In addition to the STAT pathways, PI3K/AKT and MAPK/ERK signalling pathways were also downstream of BCR-ABL signalling and may contribute to the transformation of CML cells. However, inhibition of these two pathways did not correlate with the down-regulation of PRL-3 protein in the P210 and K562 cells (Additional file2). Taken together, these data suggest PRL-3 is downstream of BCR-ABL mainly through the STAT pathway in CML.
Silencing BCR-ABL fusion gene or STAT3 decreased PRL-3 expression
To further confirm that the downregulation of PRL-3 is not due to off-target effect of Imatinib, we used small interfering RNA (siRNA) to specifically knock down the BCR-ABL fusion gene as reported by Scherr et al. qRT-PCR analysis confirmed the expression of PRL-3 gene was decreased approximate 80% in b3a2_1 siRNA transfected K562 cells, in parallel with reduction of BCR-ABL fusion genes (Figure3A) confirming that PRL-3 is downstream of BCR-ABL signalling. To assess the specific role of STAT3 in upstream regulation of PRL-3, we decreased STAT3 mRNA by using siRNA in a Nucelofection device. qRT-PCR showed that the expression of PRL-3 was reduced in STAT3 siRNA expressing K562 cells compared with the control (NC) siRNA expressing K562 cells (Figure3B). These results support the BCR-ABL and STAT3 are specific upstream regulators of PRL-3 signalling.
PRL-3 is involved in CML proliferation, self-renewal, tumorigenic capacity and drug response
To assess the functional effect of PRL-3 in CML, we knocked down PRL-3 using short-hairpin RNA (shRNA). RT-PCR analysis showed that shRNA-PRL-3 transduced K562 cells (K562-shP) demonstrated significantly reduced PRL-3 mRNA levels as compared to shRNA-scramble control transduced cells (K562-shC) (Figure4Ai). K562-shP cells proliferated as much as 2-fold slower than K562-shC at day 8 (p < 0.001) (Figure4Aii). K562-shP cells also showed significantly impaired colony generating capacity, an indicator of self-renewal capacity, by 3-fold compared to K562-shC (p < 0.001) (Figure3Aiii). We next evaluated the oncogenic role of PRL-3 in CML in vivo. Three million of K562-shC and K562-shP cells were subcutaneously inoculated into the right and left side of NOD/SCID mice, respectively (3 mice total). After 3 weeks, only K562-shC cells developed tumors at average size 800 mm3 (Figure4Aiv, right side of the animals, indicated by black circles) and average tumor weight was 0.967 ± 0.21 g (Figure4Av). These results indicate a critical role for PRL-3 in CML cell expansion, and self-renewal in vitro and in vivo. To examine if PRL-3 could be a potential therapeutic target downstream of BCR-ABL especially in TKI resistant cells with BCR-ABL mutations, we utilized RNAi to knock down PRL-3 expression in P210 T315I cells. Downregulation of mouse PRL-3 (mPRL-3) was confirmed by RT-PCR (Figure4B, left panel) and qRT-PCR (Figure4B, middle panel). Indeed, while Imatinib had no effect on P210 T315I cells, mPRL-3 silencing led to significant cell death in these cells (Figure4B, right panel).
In summary, the present study demonstrates that PRL-3 is upregulated in human CML cell lines, BCR-ABL transformed cell lines and primary CML patient samples. Interestingly, in a previous study, high expression of PRL-3 has been associated with aggressive phenotype of BCR-ABL positive acute lymphoblastic leukemia (ALL). This finding, together with our results highlight that PRL-3 is a novel downstream target of the BCR-ABL signalling pathway, and may be a novel mediator of BCR-ABL oncogenic functions such as cell survival and self-renewal. Suppression of PRL-3 could provide potential opportunity for further improving anti-CML therapy, especially in tumors with Imatinib or TKI resistant BCR-ABL mutants.
Van Etten RA: Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004, 28 (Suppl 1): S21-S28.
Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008, 112: 4808-4817. 10.1182/blood-2008-07-077958
Radich JP: Chronic myeloid leukemia 2010: where are we now and where can we go?. Hematology Am Soc Hematol Educ Program. 2010, 2010: 122-128. 10.1182/asheducation-2010.1.122
Hochhaus A: First-Line management of CML: a state of the art review. J Natl Compr Canc Netw. 2008, 6 (Suppl 2): S1-S10.
Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM: Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program). 2001: 87-112.
Hantschel O, Superti-Furga G: Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004, 5: 33-44. 10.1038/nrm1280
Sattler M, Griffin JD: Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003, 40: 4-10.
La Rosee P, Deininger MW: Resistance to imatinib: mutations and beyond. Semin Hematol. 2010, 47: 335-343. 10.1053/j.seminhematol.2010.06.005
Melo JV, Chuah C: Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology Am Soc Hematol Educ Program. 2008: 427-435.
Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA: Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002, 99: 10700-10705. 10.1073/pnas.162140299
Bessette DC, Wong PC, Pallen CJ: PRL-3: a metastasis-associated phosphatase in search of a function. Cells Tissues Organs. 2007, 185: 232-236. 10.1159/000101324
Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, Kaldis P, Giaccia AJ, Attardi LD: The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell. 2008, 30: 303-314. 10.1016/j.molcel.2008.04.002
Winter-Vann AM, Casey PJ: Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer. 2005, 5: 405-412. 10.1038/nrc1612
Al-Aidaroos AQ, Zeng Q: PRL-3 phosphatase and cancer metastasis. J Cell Biochem. 2010, 111: 1087-1098. 10.1002/jcb.22913
Stephens BJ, Han H, Gokhale V, Von Hoff DD: PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther. 2005, 4: 1653-1661. 10.1158/1535-7163.MCT-05-0248
Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B: A phosphatase associated with metastasis of colorectal cancer. Science. 2001, 294: 1343-1346. 10.1126/science.1065817
Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY: Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008, 111: 806-815. 10.1182/blood-2007-07-101139
Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, Lim SG, Zhou J, Chng WJ, Ng SB: PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell. 2010, 18: 52-62. 10.1016/j.ccr.2010.04.028
Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, Tay KG, Zeng Q, Li J, Guo K: PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One. 2011, 6: e19798- 10.1371/journal.pone.0019798
Beekman R, Valkhof M, Erkeland SJ, Taskesen E, Rockova V, Peeters JK, Valk PJ, Lowenberg B, Touw IP: Retroviral Integration Mutagenesis in Mice and Comparative Analysis in Human AML Identify Reduced PTP4A3 Expression as a Prognostic Indicator. PLoS One. 2011, 6: e26537- 10.1371/journal.pone.0026537
Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C, Zeng Q: Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011, 3: 99ra85- 10.1126/scitranslmed.3002296
Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005, 353: 172-187. 10.1056/NEJMra044389
Hehlmann R, Hochhaus A, Baccarani M: Chronic myeloid leukaemia. Lancet. 2007, 370: 342-350. 10.1016/S0140-6736(07)61165-9
Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M: Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 2003, 101: 1566-1569. 10.1182/blood-2002-06-1685
Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O’Dwyer PJ, Paietta E, Sikic BI: Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol. 2007, 25: 1341-1349. 10.1200/JCO.2006.09.3534
The authors thank Dr. Charles Chuah (Duke-NUS Graduate Medical School, Singapore) for his critical suggestions and Dr. Brian Druker (Oregon Health & Science University, USA) for providing P210 WT, P210 T315I, P210 M351T, P210 H396R cells. We are grateful to Drs. Akira Kawasaki and Akihiko Numata (Cancer Science Institute of Singapore, NUS) for sharing KCL-22. We are in debt of Prof Sir David Lane (A*Star, Singapore) for providing novel reagents and suggestions. We thank Dr. Shing-Leng Chan (Cancer Science Institute of Singapore) for providing NOD/SCID mice.
This work was supported by the Singapore National Research Foundation and the Ministry of Education under the Research Center of Excellence Program to W-J.C. W-J.C. is also supported by NMRC Clinician Scientist Investigator award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The authors declare no conflict of interests.
JZ, WJC conceptualized the original idea, designed the experiments and analyzed the data. JZ performed the experiments, wrote the paper. LLC, SCL, PSYC, SM, CB, KOKO contributed to the experiments. QZ provided critical reagents and contributed to discussions and proofread the manuscript. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 2: Figure Inhibition of MAPK/ERK and PI3K/AKT pathway activities was not correlated to down-regulation of PRL-3 protein level. (A) P210 WT and P210 T315I cells were treated with either vehicle control or various concentrations of Imatinib as indicated for 48 h. Cell lysates were used for Western blot analysis of proteins as indicated. (B) K562 cells were treated with Imatinib 0 (vehicle control), 0.2 and 1 μM for 48 h. Cells were harvested and followed by Western blot analysis of a panel of proteins shown. In both (A) and (B), β-actin was used as a loading control. MOLM-14 cell lysates were used as positive controls for p-AKT antibody. Densitometric analysis was performed using Amersham Image Scanner with LabScan ImageQuant TL Software. (DOC 528 KB)
About this article
- Chronic myeloid leukemia (CML)
- Protein-tyrosine phosphatase of regenerating liver 3 (PRL-3)
- Tyrosine kinase inhibitor (TKI)